Association Between Body Mass Index and HFNC Therapy Success
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04799132|
Recruitment Status : Completed
First Posted : March 16, 2021
Last Update Posted : March 16, 2021
|Condition or disease|
|Covid19 Obesity Overweight Pneumonia, Viral|
All adult patients over 18 years of age admitted to the intermediate care service of the participating center with suspected SARS-CoV-2 pneumonia will be considered as potential candidates for the study.
The medical records of patients in our cohort who require high-flow cannula therapy and who met all the inclusion criteria and none of the exclusion criteria will be reviewed.All data will be processed and analyzed using the SPSS 26 software once the study is completed. study sample
|Study Type :||Observational|
|Actual Enrollment :||303 participants|
|Official Title:||Association Between Body Mass Index and High-flow Cannula Therapy Success in Patients With Severe Covid 19 Related Pneumonia. Retrospective Study.|
|Actual Study Start Date :||March 11, 2020|
|Actual Primary Completion Date :||March 1, 2021|
|Actual Study Completion Date :||March 1, 2021|
- Primary outcome [ Time Frame: 1 year. ]To determine the relationship between body mass index "BMI" calculated by kg / m2 (BMI was classified in the following categories: normal weight: 18.5-24.9 kg / m2, overweight: 25-29.9 kg / m2, and obesity: ≥ 30 kg / m2) and high-flow cannula therapy success defined as: No need for mechanical ventilation.
- Demographic and laboratory characteristics [ Time Frame: 1 year ]Describe the clinical, demographic and laboratory characteristics in a population of 303 patients in Bogotá, Colombia with severe pneumonia defined by ATS criteria (confusion, urea >7 mmol/L, respiratory rate ≥30 min-1, low blood pressure, and age ≥65 years) score except age, arterial oxygen pressure/fraction inspired oxygen (PaO2/FiO2) ≤250 mmHg, multilobar infiltrates, leucopenia, thrombocytopenia, and hypothermia.) secondary to COVID 19 infection (positive C-Reactive protein) and acute hypoxemic respiratory failure defined by a PaFio2 < 300, in the intermediate care service of the Clínica del Country and Clínica La Colina, between March 2020 and March 2021.
- Body mass index as a predictor [ Time Frame: 1 year ]Evaluate the body mass index as a predictor of success in high-flow cannula therapy.
- Body mass index and HFNC success [ Time Frame: 1 year ]Evaluate the relationship between body mass index and high-flow nasal cannula therapy success.
- Mortality [ Time Frame: 1 year ]Describe the mortality of patients with high-flow cannula therapy in our medical facilities.
- Hospital stay. [ Time Frame: 1 year ]The relationship between hospital stay (days) and body mass index in our patients' cohort will be evaluated.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04799132
|Clínica del Country.|